Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials

Article

关键词: SMALL CORONARY-ARTERIES;    PALMAZ-SCHATZ STENT;    BALLOON ANGIOPLASTY;    ELECTIVE TREATMENT;    STANDARD STENT;    SLOW-RELEASE;    DOUBLE-BLIND;    NIR STENT;    RESTENOSIS;    PLACEMENT;   

DOI  :  10.1161/CIRCULATIONAHA105.570093

来源: SCIE

【 摘 要 】

Background: Binary angiographic and clinical restenosis rates can vary widely between clinical studies, even for the same stent, influenced heavily by case-mix covariates that differ among observational and randomized trials intended to assess a given stent system. We hypothesized that mean in-stent late loss might be a more stable estimator of restenosis propensity across such studies. Methods and Result: In 46 trials of drug-eluting and bare-metal stenting, increasing mean late loss was associated with higher target lesion revascularization (TLR) rates (P < 0.001). When the class of bare-metal stents was compared with the class of effective drug-eluting stents, late loss was more discriminating than TLR as measured by the high intraclass correlation coefficient (rho) (late loss, rho = 0.71 versus TLR, rho = 0.22; 95% CI of difference = 0.33, 0.65). When the individual drug-eluting stents and bare-metal stents were compared, late loss was a better discriminator than TLR (0.68 versus 0.19; 95% CI of difference = 0.24, 0.60). Greater adjustments of study covariates are needed to stabilize assessments of TLR compared with late loss because of greater influence of reference vessel diameter on TLR than on in-stent late loss. Optimization of late loss with the use of a novel method of standardization according to diabetes prevalence and mean lesion length resulted in minor adjustments in late loss (< 0.08 mm for 90% of reported trials) and an ordered array of mean late loss values for the stent systems studied. Conclusions: Late loss is more reliable than restenosis rates for discriminating restenosis propensity between new drug-eluting stent platforms across studies and might be the optimum end point for evaluating drug-eluting stents in early, nonrandomized studies.

【 授权许可】

Free